Kindling-associated SV2A expression in hilar GABAergic interneurons of the mouse dentate gyrus

Neuroscience Letters

Volumn 510, Issue 2, 2012, Pages 93-98

  Ohno, Yukihiro ^a   Okumura, Takahiro ^a   Terada, Ryo ^a   Ishihara, Shizuka ^a   Serikawa, Tadao ^b   Sasa, Masashi ^c  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c Nagisa Clinic   (Japan)

Author keywords

Dentate hilus; GABA neurons; Hippocampus; Kindling; Pentylenetetrazole; Synaptic vesicle protein 2A (SV2A)

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; GLUTAMATE DECARBOXYLASE 67; GLYCOPROTEIN; PENTETRAZOLE; SYNAPTIC VESICLE PROTEIN 2A; UNCLASSIFIED DRUG; VESICULAR GLUTAMATE TRANSPORTER 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLONIC SEIZURE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DENDRITE; DENTATE GYRUS; DENTATE HILUS; DISEASE PREDISPOSITION; EPILEPTOGENESIS; GABAERGIC TRANSMISSION; HIPPOCAMPAL CA3 REGION; HIPPOCAMPAL STRATUM LUCIDUM; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTERNEURON; KINDLING; MALE; MOUSE; NERVE ENDING; NONHUMAN; PERIKARYON; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL;

ANIMALS; CA1 REGION, HIPPOCAMPAL; CA3 REGION, HIPPOCAMPAL; DENTATE GYRUS; FLUORESCENT ANTIBODY TECHNIQUE; GABAERGIC NEURONS; INTERNEURONS; KINDLING, NEUROLOGIC; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICROSCOPY, CONFOCAL; NERVE TISSUE PROTEINS; PENTYLENETETRAZOLE; PYRAMIDAL CELLS; SYNAPTIC TRANSMISSION; VESICULAR GLUTAMATE TRANSPORT PROTEIN 1;

EID: 84856783452     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.01.009     Document Type: Article

References (31)

1. Babb T.L., Pretorius J.K., Kupfer W.R., Crandall P.H. Glutamate decarboxylase-immunoreactive neurons are preserved in human epileptic hippocampus. J. Neurosci. 1989, 9:2562-2574.
2. Bajjalieh S.M., Peterson K., Linial M., Scheller R.H. Brain contains two forms of synaptic vesicle protein 2. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:2150-2154.
3. Bajjalieh S.M., Frantz G.D., Weimann J.M., McConnell S.K., Scheller R.H. Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J. Neurosci. 1994, 14:5223-5235.
4. 2+-induced exocytosis. J. Neurosci. 2009, 29:883-897.
5. Crowder K.M., Gunther J.M., Jones T.A., Hale B.D., Zhang H.Z., Peterson M.R., Scheller R.H., Chavkin C., Bajjalieh S.M. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc. Natl. Acad. Sci. U. S. A. 1999, 96:15268-15273.
6. Custer K.L., Austin N.S., Sullivan J.M., Bajjalieh S.M. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J. Neurosci. 2006, 26:1303-1313.
7. Gu J., Lynch B.A., Anderson D., Klitgaard H., Lu S., Elashoff M., Ebert U., Potschka H., Löscher W. The antiepileptic drug levetiracetam selectively modifies kindling-induced alterations in gene expression in the temporal lobe of rats. Eur. J. Neurosci. 2004, 19:334-345.
8. Gutiérrez R., Romo-Parra H., Maqueda J., Vivar C., Ramìrez M., Morales M.A., Lamas M. Plasticity of the GABAergic phenotype of the " glutamatergic" granule cells of the rat dentate gyrus. J. Neurosci. 2003, 23:5594-5598.
9. Jahn R., Scheller R.H. SNAREs - engines for membrane fusion. Nat. Rev. Mol. Cell. Biol. 2006, 7:631-643.
10. 2+ regulators in neurotransmitter release. Neuron 1999, 24:1003-1016.
11. Kaminski R.M., Matagne A., Leclercq K., Gillard M., Michel P., Kenda B., Talaga P., Klitgaard H. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 2008, 54:715-720.
12. Kaminski R.M., Gillard M., Leclercq K., Hanon E., Lorent G., Dassesse D., Matagne A., Klitgaard H. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Epilepsia 2009, 50:1729-1740.
13. Klitgaard H., Matagne A., Gobert J., Wülfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. 1998, 353:191-206.
14. Löscher W., Hönack D., Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. 1998, 284:474-479.
15. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:9861-9866.
16. Matveeva E.A., Vanaman T.C., Whiteheart S.W., Slevin J.T. Asymmetric accumulation of hippocampal 7S SNARE complexes occurs regardless of kindling paradigm. Epilepsy Res. 2007, 73:266-274.
17. Matveeva E.A., Vanaman T.C., Whiteheart S.W., Slevin J.T. Levetiracetam prevents kindling-induced asymmetric accumulation of hippocampal 7S SNARE complexes. Epilepsia 2008, 49:1749-1758.
18. Mody I. The molecular basis of kindling. Brain Pathol. 1993, 3:395-403.
19. Morimoto K., Fahnestock M., Racine R.J. Kindling and status epilepticus models of epilepsy: rewiring the brain. Prog. Neurobiol. 2004, 73:1-60.
20. Nowack A., Yao J., Custer K.L., Bajjalieh S.M. SV2 regulates neurotransmitter release via multiple mechanisms. Am. J. Physiol. Cell Physiol. 2010, 299:C960-C967.
21. Ohno Y., Ishihara S., Terada R., Kikuta M., Sofue N., Kawai Y., Serikawa T., Sasa M. Preferential increase in the hippocampal synaptic vesicle protein 2A (SV2A) by pentylenetetrazole kindling. Biochem. Biophys. Res. Commun. 2009, 390:415-420.
22. Ohno Y., Ishihara S., Terada R., Serikawa T., Sasa M. Antiepileptogenic and anticonvulsive actions of levetiracetam in a pentylenetetrazole kindling model. Epilepsy Res. 2010, 89:360-364.
23. A receptor-mediated synaptic transmission in the rat hippocampus. Biochem. Biophys. Res. Commun. 2010, 400:117-122.
24. Ohno Y., Ishihara S., Mashimo T., Sofue N., Shimizu S., Imaoku T., Tsurumi T., Sasa M., Serikawa T. Scn1a missense mutation causes limbic hyperexcitability and vulnerability to experimental febrile seizures. Neurobiol. Dis. 2011, 41:261-269.
25. Ramírez M., Gutiérrez R. Activity-dependent expression of GAD67 in the granule cells of the rat hippocampus. Brain Res. 2001, 917:139-146.
26. Rogawski M.A., Bazil C.W. New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr. Neurol. Neurosci. Rep. 2008, 8:345-352.
27. Sato M., Racine R.J., McIntyre D.C. Kindling: basic mechanisms and clinical validity. Electroencephalogr. Clin. Neurophysiol. 1990, 76:459-472.
28. Szyndler J., Maciejak P., Turzyńska D., Sobolewska A., Lehner M., Taracha E., Walkowiak J., Skórzewska A., Wisłowska-Stanek A., Hamed A., Bidziński A., Płaźnik A. Changes in the concentration of amino acids in the hippocampus of pentylenetetrazole-kindled rats. Neurosci. Lett. 2008, 439:245-249.
29. Thind K.K., Yamawaki R., Phanwar I., Zhang G., Wen X., Buckmaster P.S. Initial loss but later excess of GABAergic synapses with dentate granule cells in a rat model of temporal lobe epilepsy. J. Comp. Neurol. 2010, 518:647-667.
30. Tirassa P., Costa N., Aloe L. CCK-8 prevents the development of kindling and regulates the GABA and NPY expression in the hippocampus of pentylenetetrazole (PTZ)-treated adult rats. Neuropharmacology 2005, 48:732-742.
31. Xu T., Bajjalieh S.M. SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat. Cell. Biol. 2001, 3:691-698.